Olga-Demetra Biziotis, Evangelia Evelyn Tsakiridis, Amr Ali, Elham Ahmadi, Jianhan Wu, Simon Wang, Bassem Mekhaeil, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Bassam Abdulkarim, Ranjan K Sur, Aruz Mesci, Peter Ellis, Tobias Berg, Jonathan L Bramson, Paola Muti, Gregory R Steinberg, Theodoros Tsakiridis
Non-small cell lung cancer (NSCLC) has a poor prognosis, and effective therapeutic strategies are lacking. The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mammalian target of rapamycin (mTOR) pathway, which mediates cell growth and survival, but it is unclear whether this drug can enhance response rates when combined with cytotoxic therapy. Here, we evaluated the effects of canagliflozin on human NSCLC response to cytotoxic therapy in tissue cultures and xenografts. Ribonucleic acid sequencing (RNA-seq), real-time quantitative PCR (RT-qPCR), metabolic function, small interfering ribonucleic acid (siRNA) knockdown, and protein expression assays were used in mechanistic analyses...
August 16, 2023: Molecular Oncology